Table 1 Characteristics of the included studies in this meta-analysis.
Author | Year | Study design | Patients No. SSA/Non-SSA | Matching factor | Approach | Tumor size SSA/Non-SSA | Remission criteria | SSA regimen | Follow-up | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
Dosage | Frequency | Duration | |||||||||
Stevenaert | 1996 | R | SSA: 64 Non-SSA: 108 | NA | TS | Micro: 33/31 (*) Macro: 31/77 (*) | 1 | Octreotide 100–500 ug | Tid | Range: 3 w-39 mo | Mean, 6.4 yr Range, 0.5–24 yr |
Biermasz | 1999 | P | SSA: 19 Non-SSA: 19 | 1, 2 | TS | Micro:5/5 Macro:14/14 | 1 | Octreotide 150–1500 ug | Qd | Mean: 5 mo Range: 1–17 mo | SSA: 5.7 ± 0.5 yr Non-SSA: 4 ± 0.6 yr |
Kristof | 1999 | P | SSA: 11 Non-SSA: 13 | Ra | TS | Macro: 11/13 | 1 | Octreotide 50–300 ug | Tid | Mean: 16.5 w | NA |
Abe | 2001 | R | SSA: 71 Non-SSA: 53 | 1 | TS | Micro: 7/14 Macro: 64/39 | 1 | Octreotide 100–1500 ug | Qd | Mean: NA Range: 3–21 mo | SSA: 51.7 ± 1.4 mo Non-SSA: 49.3 ± 2.9 mo |
Plöckinger | 2005 | R | SSA: 24 Non-SSA: 24 | 1, 2 | TS | Macro: 24/24 | 1 | Octreotide 100–500 ug | Tid | Range: 3–6 mo | SSA: > 4 yr Non-SSA: > 10 yr |
Carlsen | 2008 | RCT | SSA: 31 Non-SSA: 30 | Ra | TS | Micro: 5/5 Macro: 26/25 | 1 | Octreotide 20 mg | Every 28 d | 6 mo | SSA: > 3 mo Non-SSA: > 3 mo |
Mao | 2010 | RCT | SSA: 49 Non-SSA: 49 | Ra | TS | Macro: 49/49 | 1 | Lanreotide 30 mg | Every 1–2 w | 4 mo | SSA: > 4 mo Non-SSA: > 4 mo |
Shen | 2010 | RCT | SSA: 19 Non-SSA: 20 | Ra | TS | Macro: 19/20 | 1 | Octreotide 20 mg | Every 28 d | 3 mo | SSA: > 6 mo Non-SSA: > 6 mo |
Li | 2012 | RCT | SSA: 24 Non-SSA: 25 | Ra | TS | Macro: 24/25 | 1 | Lanreotide 30 mg | Every 1–2 w | 3 mo | SSA: > 3 mo Non-SSA: > 3 mo |
Fougner | 2014 | RCT | SSA: 31 Non-SSA: 30 | Ra | TS | Micro: 5/5 Macro: 26/25 | 1 | Octreotide 20 mg | Every 28 d | 6 mo | SSA: > 5 yr Non-SSA: > 5 yr |
Abarel | 2018 | R | SSA: 64 Non-SSA: 46 | NA | TS | Micro: 12/8 Macro: 42/33 (reported in 95 patients) | 2 | Octreotide 10–30 mg/Lanreotide 60–90 mg | Every month | Mean: 6.4 mo Range: 3–18 mo | SSA: 46.5 ± 35.2 mo Non-SSA: 57.8 ± 39.9 mo |
Lv | 2018 | R | SSA: 38 Non-SSA: 62 | NA | TS, TC | Macro: 38/62 | 1 | Octreotide 20 mg/Lanreotide 30 mg | Every 4/2 w | Median 3 m range:1–13 m | SSA: > 6 mo Non-SSA: > 6 mo |
